Cargando…
Enriching limited information on rare diseases from heterogeneous networks for drug repositioning
BACKGROUND: The historical data of rare disease is very scarce in reality, so how to perform drug repositioning for the rare disease is a great challenge. Most existing methods of drug repositioning for the rare disease usually neglect father–son information, so it is extremely difficult to predict...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596891/ https://www.ncbi.nlm.nih.gov/pubmed/34789254 http://dx.doi.org/10.1186/s12911-021-01664-x |
_version_ | 1784600491280302080 |
---|---|
author | Cao, Hongkui Zhang, Liang Jin, Bo Cheng, Shicheng Wei, Xiaopeng Che, Chao |
author_facet | Cao, Hongkui Zhang, Liang Jin, Bo Cheng, Shicheng Wei, Xiaopeng Che, Chao |
author_sort | Cao, Hongkui |
collection | PubMed |
description | BACKGROUND: The historical data of rare disease is very scarce in reality, so how to perform drug repositioning for the rare disease is a great challenge. Most existing methods of drug repositioning for the rare disease usually neglect father–son information, so it is extremely difficult to predict drugs for the rare disease. METHOD: In this paper, we focus on father–son information mining for the rare disease. We propose GRU-Cooperation-Attention-Network (GCAN) to predict drugs for the rare disease. We construct two heterogeneous networks for information enhancement, one network contains the father-nodes of the rare disease and the other network contains the son-nodes information. To bridge two heterogeneous networks, we set a mapping to connect them. What’s more, we use the biased random walk mechanism to collect the information smoothly from two heterogeneous networks, and employ a cooperation attention mechanism to enhance repositioning ability of the network. RESULT: Comparing with traditional methods, GCAN makes full use of father–son information. The experimental results on real drug data from hospitals show that GCAN outperforms state-of-the-art machine learning methods for drug repositioning. CONCLUSION: The performance of GCAN for drug repositioning is mainly limited by the insufficient scale and poor quality of the data. In future research work, we will focus on how to utilize more data such as drug molecule information and protein molecule information for the drug repositioning of the rare disease. |
format | Online Article Text |
id | pubmed-8596891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85968912021-11-17 Enriching limited information on rare diseases from heterogeneous networks for drug repositioning Cao, Hongkui Zhang, Liang Jin, Bo Cheng, Shicheng Wei, Xiaopeng Che, Chao BMC Med Inform Decis Mak Research BACKGROUND: The historical data of rare disease is very scarce in reality, so how to perform drug repositioning for the rare disease is a great challenge. Most existing methods of drug repositioning for the rare disease usually neglect father–son information, so it is extremely difficult to predict drugs for the rare disease. METHOD: In this paper, we focus on father–son information mining for the rare disease. We propose GRU-Cooperation-Attention-Network (GCAN) to predict drugs for the rare disease. We construct two heterogeneous networks for information enhancement, one network contains the father-nodes of the rare disease and the other network contains the son-nodes information. To bridge two heterogeneous networks, we set a mapping to connect them. What’s more, we use the biased random walk mechanism to collect the information smoothly from two heterogeneous networks, and employ a cooperation attention mechanism to enhance repositioning ability of the network. RESULT: Comparing with traditional methods, GCAN makes full use of father–son information. The experimental results on real drug data from hospitals show that GCAN outperforms state-of-the-art machine learning methods for drug repositioning. CONCLUSION: The performance of GCAN for drug repositioning is mainly limited by the insufficient scale and poor quality of the data. In future research work, we will focus on how to utilize more data such as drug molecule information and protein molecule information for the drug repositioning of the rare disease. BioMed Central 2021-11-16 /pmc/articles/PMC8596891/ /pubmed/34789254 http://dx.doi.org/10.1186/s12911-021-01664-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cao, Hongkui Zhang, Liang Jin, Bo Cheng, Shicheng Wei, Xiaopeng Che, Chao Enriching limited information on rare diseases from heterogeneous networks for drug repositioning |
title | Enriching limited information on rare diseases from heterogeneous networks for drug repositioning |
title_full | Enriching limited information on rare diseases from heterogeneous networks for drug repositioning |
title_fullStr | Enriching limited information on rare diseases from heterogeneous networks for drug repositioning |
title_full_unstemmed | Enriching limited information on rare diseases from heterogeneous networks for drug repositioning |
title_short | Enriching limited information on rare diseases from heterogeneous networks for drug repositioning |
title_sort | enriching limited information on rare diseases from heterogeneous networks for drug repositioning |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596891/ https://www.ncbi.nlm.nih.gov/pubmed/34789254 http://dx.doi.org/10.1186/s12911-021-01664-x |
work_keys_str_mv | AT caohongkui enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning AT zhangliang enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning AT jinbo enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning AT chengshicheng enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning AT weixiaopeng enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning AT chechao enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning |